EE177 Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the First-Line Treatment of Chronic Lymphocytic Leukemia in Brazil
Abstract
Authors
Ian Keary Marília Hernani Carolina Meyn Teixeira Ricardo Paranhos Moreira Sr. Barry Rodgers-Gray John Fullarton MELDA DINC Sarah Palazuelos-Munoz Fady Fam Doreen Tay